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Supplementary Table 1. Sixty-three methylation-prostate cancer associations independent from prostate cancer risk variantsa for CpG 
sites at prostate cancer risk loci  
 
CpG site Chr 
Position 




P value after 
adjusting for 
risk SNPe 
cg14454477 2 43903900 intronic 0.10 0.89 (0.85-0.93) 1.85 × 10-8 rs1465618 350.0 2.61 × 10-7 
cg10804687 6 29859520 downstream 0.05 1.22 (1.14-1.30) 5.62 × 10-9 rs7767188 214.3 5.45 × 10-8 
cg19872019 6 29980960 ncRNA_exonic 0.06 0.82 (0.78-0.87) 6.37 × 10-12 rs7767188 92.8 5.14 × 10-7 
cg03553308 6 30069250 intergenic 0.22 0.91 (0.89-0.93) 3.52 × 10-14 rs7767188 4.5 3.19 × 10-8 
cg24064041 6 30165027 intronic 0.18 0.91 (0.89-0.94) 3.36 × 10-9 rs12665339 436.2 2.10 × 10-7 
cg02541301 6 30166173 intronic 0.02 0.73 (0.67-0.80) 7.44 × 10-11 rs12665339 435.1 2.54 × 10-8 
cg09609649 6 30458060 exonic 0.02 0.75 (0.69-0.82) 3.55 × 10-10 rs12665339 143.2 4.49 × 10-8 
cg19109457 6 30460484 intronic 0.23 1.07 (1.04-1.10) 1.56 × 10-7 rs12665339 140.7 6.09 × 10-7 
cg08743794 6 30656577 exonic 0.01 0.55 (0.48-0.63) 2.71 × 10-18 rs12665339 55.3 8.57 × 10-17 
cg26004235 6 30656582 exonic 0.01 0.72 (0.66-0.79) 7.71 × 10-12 rs12665339 55.4 9.51 × 10-8 
cg06206827 6 30709045 exonic 0.05 0.84 (0.80-0.88) 5.80 × 10-13 rs12665339 107.8 1.33 × 10-8 
cg17067528 6 30712517 upstream 0.01 0.79 (0.73-0.86) 8.02 × 10-9 rs12665339 111.3 3.98 × 10-7 
cg08951271 6 30850543 UTR5 0.06 0.80 (0.75-0.85) 1.64 × 10-12 rs2596546 478.8 2.51 × 10-7 
cg12433575 6 30881464 intronic 0.02 0.72 (0.66-0.78) 6.48 × 10-15 rs2596546 447.9 3.19 × 10-12 
cg26467571 6 30882355 intronic 0.03 0.76 (0.70-0.82) 4.03 × 10-12 rs2596546 447.0 6.07 × 10-7 
cg16958594 6 30882708 exonic 0.69 0.96 (0.95-0.97) 5.08 × 10-9 rs2596546 446.7 7.86 × 10-8 
cg15978899 6 30882994 exonic 0.59 0.96 (0.94-0.97) 2.38 × 10-9 rs2596546 446.4 5.85 × 10-9 
cg00933603 6 30883001 exonic 0.61 0.96 (0.94-0.97) 1.52 × 10-8 rs2596546 446.4 4.06 × 10-8 
cg10158679 6 30883074 intronic 0.61 0.96 (0.94-0.97) 5.48 × 10-9 rs2596546 446.3 2.71 × 10-8 
cg00244776 6 30883192 exonic 0.51 0.95 (0.94-0.97) 2.13 × 10-8 rs2596546 446.2 5.29 × 10-8 
cg02149965 6 30883203 exonic 0.55 0.95 (0.94-0.97) 5.94 × 10-10 rs2596546 446.2 8.70 × 10-9 
cg08827454 6 30922981 
upstream/downst
ream 0.06 0.84 (0.80-0.89) 1.25 × 10-10 rs2596546 406.4 5.69 × 10-7 
cg03059420 6 30923241 upstream 0.02 0.70 (0.64-0.77) 2.02 × 10-13 rs2596546 406.1 5.16 × 10-12 
cg11935153 6 30923306 upstream 0.06 0.86 (0.82-0.91) 4.61 × 10-8 rs2596546 406.1 2.21 × 10-8 
cg15878568 6 30923865 intergenic 0.21 0.92 (0.90-0.95) 7.14 × 10-9 rs2596546 405.5 1.93 × 10-8 
cg11934771 6 31021796 intronic 0.08 1.24 (1.18-1.30) 5.19 × 10-19 rs2596546 307.6 1.64 × 10-8 
cg08961072 6 31591771 intronic 0.01 0.69 (0.62-0.77) 1.51 × 10-12 rs2596546 262.4 1.24 × 10-7 
cg16220567 6 31631762 exonic 0.06 1.15 (1.10-1.20) 8.98 × 10-9 rs2596546 302.4 1.33 × 10-7 
cg06670599 6 31631801 exonic 0.05 1.16 (1.10-1.22) 1.66 × 10-7 rs2596546 302.4 4.61 × 10-7 
cg22786465 6 31649502 intergenic 0.04 1.23 (1.15-1.31) 7.28 × 10-10 rs2596546 320.1 9.86 × 10-9 
cg22708150 6 31649619 intergenic 0.04 1.18 (1.12-1.24) 1.31 × 10-9 rs2596546 320.2 1.43 × 10-8 
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cg21036162 6 31649728 intergenic 0.03 1.28 (1.19-1.38) 1.39 × 10-10 rs2596546 320.3 5.18 × 10-8 
cg24520975 6 31651362 intergenic 0.10 1.15 (1.10-1.20) 6.87 × 10-10 rs2596546 322.0 4.49 × 10-8 
cg17391620 6 31734471 exonic 0.07 1.17 (1.12-1.23) 2.19 × 10-11 rs2596546 405.1 4.05 × 10-7 
cg26472225 6 31832238 intronic 0.03 1.37 (1.25-1.50) 5.95 × 10-11 rs3096702 360.1 3.74 × 10-7 
cg10917426 6 31867698 UTR3 0.04 0.78 (0.73-0.83) 1.19 × 10-13 rs3096702 324.6 1.24 × 10-8 
cg08975528 6 31867700 UTR3 0.02 0.69 (0.63-0.76) 1.85 × 10-14 rs3096702 324.6 2.31 × 10-10 
cg07180897 6 32729130 intronic 0.64 1.04 (1.03-1.06) 3.17 × 10-8 rs3129859 328.2 3.98 × 10-7 
cg00755130 6 32729587 exonic 0.21 0.91 (0.89-0.93) 4.53 × 10-15 rs3129859 328.6 2.17 × 10-7 
cg27160348 6 32729590 exonic 0.21 0.89 (0.87-0.92) 1.53 × 10-17 rs3129859 328.7 1.05 × 10-7 
cg25736982 6 160182554 ncRNA_exonic 0.21 0.92 (0.90-0.95) 4.80 × 10-9 rs651164 398.8 1.21 × 10-8 
cg23829577 6 160183769 exonic 0.04 0.80 (0.74-0.86) 4.70 × 10-9 rs651164 397.6 1.21 × 10-7 
cg21110739 6 160768369 intergenic 0.02 2.03 (1.73-2.39) 1.12 × 10-17 rs4646284 186.8 9.37 × 10-10 
cg25313204 6 160768801 upstream 0.08 1.17 (1.13-1.22) 7.46 × 10-17 rs4646284 187.3 3.23 × 10-11 
cg23898998 6 160782998 intronic 0.08 1.35 (1.27-1.43) 2.61 × 10-22 rs4646284 201.5 1.73 × 10-11 
cg14550828 6 160876992 intergenic 0.02 1.61 (1.47-1.77) 6.18 × 10-23 rs4646284 295.4 2.23 × 10-13 
cg12196573 7 27195602 intronic 0.01 1.30 (1.18-1.44) 1.97 × 10-7 rs200362064 395.6 1.70 × 10-7 
cg02643054 7 27206544 ncRNA_intronic 0.02 1.31 (1.20-1.42) 2.07 × 10-10 rs200362064 384.7 7.77 × 10-9 
cg06795527 7 27245018 ncRNA_exonic 0.10 0.87 (0.84-0.91) 2.47 × 10-11 rs200362064 346.2 3.75 × 10-9 
cg16196175 7 27289120 intergenic 0.02 0.74 (0.67-0.81) 3.19 × 10-10 rs200362064 302.1 3.15 × 10-8 
cg06521347 8 128139451 intergenic 0.09 0.79 (0.75-0.82) 1.17 × 10-27 rs11986220 392.2 1.11 × 10-27 
cg23203918 8 128235836 intergenic 0.05 1.30 (1.23-1.38) 5.59 × 10-20 rs11986220 295.9 1.25 × 10-24 
cg17095489 8 128264282 ncRNA_intronic 0.03 0.69 (0.64-0.75) 2.16 × 10-21 rs11986220 267.4 1.97 × 10-33 
cg15704662 8 128388831 ncRNA_intronic 0.07 0.82 (0.78-0.87) 8.12 × 10-13 rs10505477 18.6 2.61 × 10-18 
cg14289643 8 128428869 exonic 0.02 0.47 (0.43-0.51) 1.70 × 10-57 rs6983267 15.6 3.05 × 10-8 
cg14036981 11 68920648 ncRNA_intronic 0.24 1.07 (1.05-1.10) 3.04 × 10-8 rs12275055 60.7 1.49 × 10-7 
cg25179853 11 68924577 ncRNA_intronic 0.12 1.20 (1.16-1.25) 7.56 × 10-24 rs12275055 56.8 2.32 × 10-10 
cg23740940 11 68924746 ncRNA_intronic 0.32 1.10 (1.08-1.12) 1.37 × 10-20 rs12275055 56.6 1.69 × 10-12 
cg07882059 11 68924751 ncRNA_intronic 0.34 1.09 (1.07-1.11) 1.17 × 10-16 rs12275055 56.6 4.52 × 10-11 
cg03469862 11 68924853 ncRNA_intronic 0.28 1.11 (1.08-1.13) 4.16 × 10-21 rs12275055 56.5 4.40 × 10-14 
cg26453588 22 43506021 upstream 0.21 1.29 (1.25-1.32) 3.66 × 10-67 rs5759167 5.8 4.14 × 10-18 
cg04042468 22 43506033 upstream 0.15 1.34 (1.30-1.39) 2.10 × 10-70 rs5759167 5.8 3.64 × 10-15 
cg20550677 22 43506316 upstream 0.07 1.68 (1.59-1.78) 4.23 × 10-72 rs5759167 6.1 3.44 × 10-13 
a Risk SNPs identified in previous GWAS or fine-mapping studies. 
b R2: model prediction performance (R2) derived using FHS data. 
c OR (odds ratio) and CI (confidence interval) per one standard deviation increase in genetically predicted DNA methylation 
d P value: derived from association analyses of 79,194 cases and 61,112 controls (two-sided); associations with p≤6.47×10-7 based on Bonferroni 
correction of 77,243 tests (0.05/77,243) were shown; 
e using COJO method 
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Supplementary Table 2. Genomic annotation of prostate cancer associated CpG site locations. Categories were annotated through 
ANNOVAR. Substantial inflations of “exonic” and “ncRNA_exonic”, and substantial decreased proportion of “intergenic” are found 
for prostate cancer associated CpG sites compared with the overall tested 77,243 CpG sites.  
 
Classification 
Identified CpG sites 
associated with prostate 
cancer risk (n=759) 
Overall tested CpG sites 
(N=77,243) P for difference 
intronic 268 (35.31%) 28053 (36.32%) 0.59 
intergenic 117 (15.42%) 19388 (25.10%) 1.13 × 10-9 
upstream 87 (11.46%) 10912 (14.13%) 0.04 
exonic 116 (15.28%) 5749 (7.44%) 6.36 × 10-16 
ncRNA_intronic 52 (6.85%) 4184 (5.42%) 0.10 
5’-UTR 28 (3.69%) 3075 (3.98%) 0.75 
3’-UTR 35 (4.61%) 2765 (3.58%) 0.15 
ncRNA_exonic 42 (5.53%) 1868 (2.42%) 6.37 × 10-8 
downstream 8 (1.05%) 795 (1.03%) 1.00 
upstream;downstream 6 (0.79%) 426 (0.55%) 0.52 
splicing 0 (0.00%) 17 (0.02%) 1.00 
5’-UTR; 3’-UTR 0 (0.00%) 8 (0.01%) 1.00 
exonic;splicing 0 (0.00%) 1 (0.001%) 1.00 
ncRNA_splicing 0 (0.00%) 2 (0.003%) 1.00 
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Supplementary Table 3. Associations between methylation levels of prostate cancer associated CpG sites and expression of 
annotated adjacent genes in white blood cells in the Framingham Heart Study* 
 
CpG site Adjacent gene  Classification Association beta 
Association P 
valuea 
cg01799818 VPS53 intronic 0.09 4.81 × 10-4 
cg13731761 C11orf21 exonic -0.21 2.20 × 10-14 
cg26598899 C11orf21 exonic -0.18 1.03 × 10-11 
cg21162977 RRAGA exonic -0.09 8.82 × 10-4 
cg26751972 HLA-F exonic -0.15 1.43 × 10-8 
cg24064041 TRIM26 intronic 0.13 8.69 × 10-7 
cg00266604 TRIM26 intronic -0.10 3.84 × 10-4 
cg12001709 MICB intronic 0.10 1.73 × 10-4 
cg10970124 CSNK2B UTR5 -0.10 2.88 × 10-4 
cg13892322 LY6G5C upstream -0.12 4.42 × 10-6 
cg22786465 LY6G5C downstream 0.08 2.49 × 10-3 
cg02733847 LY6G5C downstream 0.11 1.05 × 10-4 
cg25769566 LY6G5C downstream 0.26 <2.00 × 10-16 
cg24520975 LY6G5C downstream 0.10 2.37 × 10-4 
cg13197078 C4B intronic -0.13 3.24 × 10-6 
cg11239749 HLA-DOB intronic 0.20 3.81 × 10-14 
cg19350197 HLA-DOB exonic 0.24 <2.00 × 10-16 
cg25824217 HLA-DPA1 intronic 0.16 2.69 × 10-9 
cg07306190 UHRF1BP1 intronic -0.33 < 2.00 × 10-16 
cg10288850 MCAT upstream -0.09 8.52 × 10-4 
cg06298701 NCOA4 intronic -0.08 1.90 × 10-3 
cg17620335 NCOA4 intronic -0.08 2.51 × 10-3 
cg01330312 NCOA4 intronic -0.12 1.28 × 10-5 
cg07185131 EHBP1 upstream -0.08 2.61 × 10-3 
cg01715842 ZDHHC7 upstream -0.09 6.68 × 10-4 
cg20056908 VAMP8 UTR3 0.20 3.03 × 10-14 
cg02652597 VAMP5 upstream -0.16 8.76 × 10-9 
cg15059474 BAIAP2L1 intronic 0.11 9.72 × 10-5 
cg08336300 SESN1 intronic -0.11 2.34 × 10-5 
cg17117243 SESN1 intronic -0.15 1.87 × 10-8 
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cg07128416 CFAP44 upstream 0.09 6.67 × 10-4 
cg07054641 CFAP44 upstream 0.09 6.47 × 10-4 
cg20138861 GPR160 intronic -0.11 5.97 × 10-5 
cg10165864 PDK1 upstream -0.14 9.34 × 10-8 
cg16797009 PDK1 downstream -0.17 3.52 × 10-10 
cg25053018 PDK1 downstream 0.11 3.10 × 10-5 
cg20240347 PIK3C2B downstream 0.11 2.59 × 10-5 
cg20240347 MDM4 upstream 0.21 1.69 × 10-14 
cg15199181 NUCKS1 upstream -0.08 2.18 × 10-3 
cg14893161 PM20D1 UTR5 -0.08 2.70 × 10-3 
cg07167872 PM20D1 upstream -0.08 1.83 × 10-3 
cg24503407 PM20D1 upstream -0.08 2.78 × 10-3 
cg07157834 PM20D1 upstream -0.08 2.12 × 10-3 
 
* Linear regression analyses (two-sided) adjusted for covariates of age, sex, top PCs and estimated cell type compositions 
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Supplementary Table 4. Associations between methylation levels of prostate cancer associated CpG sites and expression of genes 










cg10917426 ZBTB12 ZBTB ENSP00000364677 UTR3 0.06 0.04 
cg19376664 
PBX2 Homeobox ENSP00000364190 
UTR3 -0.08 0.005 
cg14538532 UTR3 -0.06 0.02 
cg06431527 upstream 0.05 0.05 
cg24038745 POU5F1 Pou ENSP00000495779;ENSP00000419298; exonic -0.05 0.05 
cg26416811 RFX6 RFX ENSP00000332208; upstream -0.07 0.009 
cg03510041 FOXP4 Fork_head 
ENSP00000362154;ENSP00000386958;ENSP00000309823; 
ENSP00000362151;ENSP00000362148; intronic -0.07 0.01 
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Supplementary Table 5. Associations between methylation levels of prostate cancer associated CpG sites and expression of 
annotated adjacent genes in tumor adjacent normal prostate tissue samples in The Cancer Genome Atlas 
 
CpG site Adjacent gene  Classification Association beta Association P valuea 
cg01799818 VPS53 intronic -0.17 0.32 
cg13731761* C11orf21 exonic -0.35 0.04 
cg26598899* C11orf21 exonic -0.57 0.0004 
cg21162977* RRAGA exonic -0.13 0.45 
cg26751972* HLA-F exonic -0.28 0.11 
cg24064041 TRIM26 intronic -0.06 0.73 
cg12001709* MICB intronic 0.29 0.10 
cg10970124* CSNK2B UTR5 -0.17 0.34 
cg22786465* LY6G5C downstream 0.47 0.0052 
cg02733847* LY6G5C downstream 0.17 0.34 
cg25769566* LY6G5C downstream 0.30 0.08 
cg24520975* LY6G5C downstream 0.38 0.03 
cg11239749* HLA-DOB intronic 0.13 0.46 
cg19350197 HLA-DOB exonic -0.24 0.17 
cg25824217 HLA-DPA1 intronic -0.62 1.02 × 10-4 
cg07306190* UHRF1BP1 intronic -0.10 0.56 
cg06298701* NCOA4 intronic -0.10 0.57 
cg17620335* NCOA4 intronic -0.17 0.33 
cg07185131 EHBP1 upstream 0.06 0.72 
cg01715842* ZDHHC7 upstream -0.25 0.15 
cg20056908 VAMP8 UTR3 -0.03 0.86 
cg02652597* VAMP5 upstream -0.37 0.03 
cg15059474 BAIAP2L1 intronic -0.34 0.05 
cg08336300* SESN1 intronic -0.04 0.81 
cg17117243* SESN1 intronic -0.26 0.14 
cg07128416 CFAP44 upstream -0.03 0.89 
cg07054641 CFAP44 upstream -0.15 0.39 
cg20138861 GPR160 intronic 0.05 0.78 
cg10165864* PDK1 upstream -0.38 0.03 
cg16797009* PDK1 downstream -0.05 0.77 
cg20240347 PIK3C2B downstream -0.11 0.55 
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cg20240347* MDM4 upstream 0.10 0.59 
cg15199181* NUCKS1 upstream -0.62 1.01 × 10-4 
cg14893161* PM20D1 UTR5 -0.57 4.81 × 10-4 
cg07167872* PM20D1 upstream -0.67 1.45 × 10-5 
cg24503407* PM20D1 upstream -0.69 6.00 × 10-6 
cg07157834* PM20D1 upstream -0.77 1.17 × 10-7 
  
* represents association with the same direction of effect compared to the association of the corresponding gene-CpG site in blood tissue; 
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Supplementary Table 6. Canonical pathways, diseases, bio functions and networks associated with the genes of interest. 
 
Top canonical pathways Top diseases and disorders Molecular and cellular 
functions 
Top networks 
Cell Cycle: G2/M DNA Damage 
Checkpoint 
Regulation; 
Cancer Drug Resistance By Drug 
Efflux 
Developmental Disorder; 
Endocrine System Disorders; 
Hereditary Disorder; 
Neurological Disease; 
Organismal Injury and Abnormalities 
Cell Death and Survival; 
Lipid Metabolism; 
Molecular Transport; 
Small Molecule Biochemistry; 
Cellular Development 
Cell Death and Survival, Cell 
Morphology, Hematological Disease; 
Developmental Disorder, Hereditary 
Disorder, Neurological Disease; 
Infectious Diseases, Post-Translational 
Modification, Respiratory Disease; 
Cell Cycle, Cellular Movement, 
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Supplementary Table 7. Significant three-way associations with inconsistent direction of effect for methylation-gene expression-
prostate cancer risk pathway 
 




and prostate cancer 
risk 
DNA methylation and 
gene expression 
Gene expression 
and prostate cancer 
risk 




value OR P value 
cg20056908 2 85808945 VAMP8 UTR3 1.09 1.63 × 10-11 0.20 3.03 × 10-14 0.66 1.37 × 10-3 
cg13197078 6 31963919 C4B intronic 0.92 1.04 × 10-7 -0.13 3.24 × 10-6 0.92 3.65 × 10-8 
cg15059474 7 97990184 BAIAP2L1 intronic 0.92 2.64 × 10-9 0.11 9.72 × 10-5 2.21 5.86 × 10-17 
cg06298701 10 51566673 
NCOA4 





cg17620335 10 51566824 intronic 1.22 4.44 × 10-34 -0.08 2.51 × 10-3 
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DNA methylation that could be predicted well in FHS also tended to be predicted well in WHI (a correlation coefficient of 0.96 for R2 
in two data sets 
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Supplementary Figure 2. Enrichment of prostate cancer associated CpG sites in regions overlapping H3K4me1 markers from 




There tends to be an overlap of their positions with regions containing lysine 4 mono-methylated H3 histone (H3K4me1) markers across 
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